Renovo - Large upside potential
Renovo is a debt free, fully funded, biopharmaceutical product company, specialising in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. It aims to be first to market with a scar reduction pharmaceutical drug in the US and Europe. Its pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.
It is reaching a crucial stage within the next 6 to 9 months, with its key Juvista product due to report phase III EU trial results in the first half of 2011. A successful trial would be very very good news & I’d expect the share price to be much higher than the current 25p level. The CEO reckons “multiples” of the current share price, but then he would say that wouldn’t he! Protecting the downside on a negative result is the fact they will have £25m to £30m in cash in mid 2011, no debt and have several other promising products in their pipeline.
There is other newsflow potential whilst waiting for the Juvista results, with Renovo targeting a cosmetic partner agreement for Juvidex which could quickly generate royalty income and they are also seeking partners to exploit Juvista in the large South American & Asian markets.
With a market cap of £48m at 25p and net cash of over £50m, Renovo looks like an excellent risk/reward play at the current price. Given the large volume in the past few trading days it appears others believe so to. RunningCapital took a position of 20,000 shares on Monday at 25p.
Posted in Shares having 2 comments »




